| Autor: |
Barraclough JY; The George Institute for Global Health, University of New South Wales, Sydney, NSW 2042, Australia.; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia., Patel S; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.; Sydney Medical School, University of Sydney, Sydney, NSW 2042, Australia., Yu J; The George Institute for Global Health, University of New South Wales, Sydney, NSW 2042, Australia., Neal B; The George Institute for Global Health, University of New South Wales, Sydney, NSW 2042, Australia., Arnott C; The George Institute for Global Health, University of New South Wales, Sydney, NSW 2042, Australia.; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.; Sydney Medical School, University of Sydney, Sydney, NSW 2042, Australia. |
| Abstrakt: |
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medication with broad cardiovascular benefits in those with type 2 diabetes, chronic kidney disease, and heart failure. These include reductions in major adverse cardiac events and cardiovascular death. The mechanisms that underlie their benefits in atherosclerotic cardiovascular disease (ASCVD) are not well understood, but they extend beyond glucose lowering. This narrative review summarises the ASCVD benefits of SGLT2 inhibitors seen in large human outcome trials, as well as the mechanisms of action explored in rodent and small human studies. Potential pathways include favourable alterations in lipid metabolism, inflammation, and endothelial function. These all require further investigation in large human clinical trials with mechanistic endpoints, to further elucidate the disease modifying benefits of this drug class and those who will benefit most from it. |
